Aim:

To analyze the clinical experience with abiraterone acetate in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (MCRPC), in a real-world setting at a medical center in Mexico City.

Materials and Methods:

An observational study was conducted on CN patients with MCRPC seen at the Urology Department of the Centro Médico Nacional “20 de Noviembre” of the ISSSTE. They were given abiraterone acetate plus prednisone and leuprolide, within the time frame of January 2014 to December 2016. The primary endpoints were time to radiologic progression and overall survival. The secondary endpoints were the times to ECOG status decline, cytotoxic chemotherapy commencement, analgesic use, and PSA progression. All the variables were compared in subgroups, divided by Gleason score.

Results:

Eighteen patients received abiraterone acetate. Radiologic progression was observed after 7 and 10 months (2 cases, 11.1%) and death (1 case, 5.5%) occurred after 9 months. Early analgesic use was frequent (>50% at 10 months), whereas disease progression, indicated by the beginning of chemotherapy, a rise in the ECOG score, or an increase in PSA value, occurred in <50%. We also observed a trend towards earlier chemotherapy commencement, ECOG progression, and analgesic use, if the Gleason score was >7. Thirteen (72.2%) patients presented with the adverse events of fatigue, back pain, hot flashes, and others, none of which were fatal.

Conclusion:

Abiraterone acetate therapy was as safe and efficacious in the real-world setting of our study sample, as in previous reports in the medical literature, suggesting that it can be a valuable therapeutic option in similar populations.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )